Evidence map›Paper›PMID 32792532›Full record

ArticleScientific reports2020

Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes.

Prashanth Prithviraj, Matthew Anaka, Erik W Thompson, Revati Sharma, Marzena Walkiewicz, Candani S A Tutuka, Andreas Behren, George Kannourakis, Aparna Jayachandran

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. mCell biology and toxicology · 2023
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

Prashanth PrithvirajCancer Immunobiology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.
Matthew AnakaDepartment of Medicine, University of Alberta, Alberta, Canada.
Erik W ThompsonInstitute of Health and Biomedical Innovation, Queensland University of Technology (QUT), Brisbane, Australia.
Revati SharmaFiona Elsey Cancer Research Institute, Ballarat Technology Park- Central Suite 23, 106-110 Lydiard St Sth, Ballarat, VIC, 3350, Australia.
Marzena WalkiewiczCancer Immunobiology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.
Candani S A TutukaCancer Immunobiology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.
Andreas BehrenCancer Immunobiology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.ORCID http://orcid.org/0000-0001-5329-280X
George KannourakisFiona Elsey Cancer Research Institute, Ballarat Technology Park- Central Suite 23, 106-110 Lydiard St Sth, Ballarat, VIC, 3350, Australia.
Aparna JayachandranFiona Elsey Cancer Research Institute, Ballarat Technology Park- Central Suite 23, 106-110 Lydiard St Sth, Ballarat, VIC, 3350, Australia. aparna@fecri.org.au.
Federation University · AUBallarat Health Services · AULa Trobe University · AUOlivia Newton-John Cancer Wellness & Research Centre · AUThe University of Melbourne · AUTranslational Research Institute · AUUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elevated levels of pregnancy-associated plasma protein-A (PAPP-A) have been implicated in the pathogenesis of various malignancies, including breast cancers. Breast cancer is one of the most frequent carcinomas and is the second most common cancer type detected in women of child-bearing age. Throughout pregnancy PAPP-A is produced and secreted by the placental syncytiotrophoblast cells; co-incidentally pregnancy-associated breast cancers often have an aggressive clinical course. The components of the PAPP-A/IGF axis was assessed in a panel of breast cancer cell lines. Using neutralising antibodies the impact of PAPP-A/IGF axis on cell motility was evaluated. PAPP-A was expressed in four of the twelve breast cancer cell lines tested. Blocking PAPP-A and IGFBP4 with neutralising antibodies significantly decreased motiliy of MDA-MB-231 cells. Upregulation of PAPP-A expression in breast tumours resulted in a trend towards worse overall survival. Notably, PAPP-A expression also positively correlated with epithelial-to-mesenchymal transition markers. In conclusion, these results indicate that PAPP-A plays an important role in breast cancer progression and it may be a promising therapeutic target in breast cancer.

Indexed as

Disease ProgressionAntibodies, NeutralizingBreast NeoplasmsCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionFemaleHumansInsulin-Like Growth Factor Binding Protein 4Insulin-Like Growth Factor INeoplasm InvasivenessPregnancyPregnancy-Associated Plasma Protein-APrognosisTrophoblastsAntibodies, NeutralizingIGF1 protein, humanIGFBP4 protein, humanInsulin-Like Growth Factor Binding Protein 4Insulin-Like Growth Factor IPAPPA protein, humanPregnancy-Associated Plasma Protein-A

Identifiers

PMID32792532
PMCPMC7426935
OpenAlexW3048370183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.